SEQUENT Q2 FY26 Results & Earnings Analysis
Sentiment: Good
Earnings Summary
SeQuent reported strong Q2 FY26 results with 15% YoY revenue growth, 330 bps EBITDA margin expansion to 15.5%, and PAT nearly tripling. The NCLT-approved merger with Viyash creates a transformed entity focused on companion animals and global expansion. Management guided for sustained double-digit growth and 20%+ EBITDA margins, with significant synergy benefits expected from manufacturing and R&D integration over next 12-18 months.
Management Tone
- Prepared Remarks: —
- Q&A Session: —
Growth vs Margin Focus
Management emphasizes balanced approach with continuous focus on improving gross margins while maintaining double-digit revenue growth through product optimization and operational efficiencies. ,
About SeQuent Scientific Limited
SeQuent Scientific Limited (SEQUENT) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.